Conference
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
Authors
Macaulay VM; Middleton MR; Eckhardt SG; Juergens RA; Rudin CM; Manukyants A; Gogov S; Poondru S; Gedrich R; Gadgeel SM
Volume
29
Pagination
pp. 3098-3098
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2011
DOI
10.1200/jco.2011.29.15_suppl.3098
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X